A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.
1. Nine severe rapid cycling manic-depressive patients were treated with a magnesium preparation, Magnesiocard 40 mEq/day in an open label study for a period up to 32 weeks. 2. Magnesiocard was found to have clinical results at least equivalent to those of lithium in about 50% of these patients. These results were obtained in an exploratory study and should be interpreted with caution. 3. The possibility that Magnesiocard could replace or improve the efficacy of lithium as a preventive treatment of manic-depressive illness merits further clinical investigation.
Chouinard
G
G
Research Centre, Louis-H. Lafontaine Hospital, University of Montreal, Canada.
Beauclair
L
L
Geiser
R
R
Etienne
P
P
D001224:Aspartic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D006801:Humans; D008274:Magnesium / Q000009:adverse effects / Q000627:therapeutic use*; D019964:Mood Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011188:Potassium / Q000097:blood; D012107:Research Design; D012964:Sodium / Q000097:blood
D001224:Aspartic Acid; D012964:Sodium; D008274:Magnesium; D011188:Potassium; D002118:Calcium